Switch to lansoprazole: failure not more costly

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1301, 2001-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switch to lansoprazole: failure not more costly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 326, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Failure of initial antibacterial therapy costly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 492, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Graded activity no more effective, no less costly in OA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 528, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

RA: leflunomide more costly than methotrexate

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 350, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Fewer but more costly medicines are being sold in Germany

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 272, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite